Insufficient
This paper presents a hypothesis-generating perspective piece examining the potential interaction between amylin-based therapies — including the pramlintide and cagrilintide receptor agonists, and the combination therapy CagriSema — and the renin-angiotensin system (RAS). The authors hypothesize that amylin receptor agonists may activate the RAS, which could potentially counteract the cardiorenal benefits of these obesity and type 2 diabetes treatments. However, they note the paradox that CagriSema demonstrated meaningful blood pressure reductions in phase 3 trials. The authors further hypothesize that concurrent use of RAS inhibitors (ACE inhibitors or angiotensin-receptor blockers) may redirect amylin-induced RAS activation toward the protective "alternative RAS pathway," promoting vasodilatory, anti-inflammatory, and antiproliferative effects via Mas receptors. To test these hypotheses, the authors propose a research agenda encompassing preclinical studies, post-hoc trial analyses stratified by RAS inhibitor use, biomarker studies, and prospective mechanistic human studies. No original experimental data are presented. Key limitations include the entirely speculative nature of the central claims, the absence of direct supporting evidence, and reliance on inference from existing trial-level observations.
Lancet (London, England) · Nov 2025DOI ↗ Insufficient
This paper reports the baseline characteristics of participants enrolled in SYNCHRONIZE-1, a multinational, randomized, double-blind, placebo-controlled Phase 3 trial evaluating survodutide — a dual glucagon receptor and GLP-1 receptor agonist — for weight management in adults with obesity but without type 2 diabetes. A total of 725 participants from 14 countries were randomized 1:1:1 to receive once-weekly subcutaneous injections of survodutide (up-titrated to 3.6 mg or 6.0 mg) or placebo over 76 weeks. At baseline, participants had a mean age of 47.1 years, mean BMI of 37.9 kg/m², and mean waist circumference of 115.2 cm; 59.4% were female. Common obesity-related complications included hypertension (40.0%), dyslipidaemia (33.7%), and prediabetes (30.2%). The primary endpoints are percent body weight change and achievement of ≥5% body weight reduction from baseline to Week 76. As this publication covers only baseline data, no efficacy or safety outcomes are yet reported. The study's key limitation at this stage is that it describes enrollment characteristics only, with no outcome data available.
Diabetes, obesity & metabolism · Nov 2025DOI ↗ Insufficient
This study focused on the development and validation of an analytical detection method — not a clinical intervention — for identifying growth hormone-releasing hormone (GHRH) and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) in human urine samples for anti-doping purposes. These peptides are banned by the World Anti-Doping Agency (WADA) due to their potential performance-enhancing effects. The researchers developed a nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) approach, systematically optimizing sample preparation steps including solid-phase extraction (SPE) and ultrafiltration. The finalized workflow — ultrafiltration followed by SPE — was fully validated per WADA guidelines, assessing selectivity, reliability, limits of detection (LOD ≤ 0.5 ng/mL), limits of identification (LOI 0.5–0.75 ng/mL), carryover, robustness, autosampler stability, and matrix effects. The method demonstrated sufficient sensitivity for both screening and confirmation of target peptides in urine. A key limitation is that this is a purely analytical/methodological study; it provides no clinical, pharmacological, or physiological data about the effects of these peptides in humans, and its findings are confined to laboratory detection performance.
Journal of pharmaceutical and biomedical analysis · Oct 2025DOI ↗ Insufficient
This paper is a published correspondence ("Reply") in the journal Pharmaceuticals, in which the original authors of a literature and patent review on the BPC 157 peptide respond to a commentary submitted by Sikiric et al. The reply addresses points raised in the comment regarding BPC 157's proposed mechanisms of action, specifically its purported roles in modulating angiogenesis and nitric oxide (NO) pathways. The responders engage with the argument that BPC 157 may selectively target the cytotoxic and damaging aspects of NO signaling while preserving or restoring its essential protective physiological functions. As a correspondence piece reacting to a comment on a review article, this paper does not present new experimental data, clinical trials, or original preclinical findings. Its contribution is interpretive and editorial in nature, clarifying the scope and conclusions of the original review in light of the mechanistic claims put forth by the commentators. Limitations include the absence of any new empirical evidence; all mechanistic claims discussed are derived from previously published literature cited by both parties.
Pharmaceuticals (Basel, Switzerland) · Sep 2025DOI ↗ Insufficient
This paper presents the protocol for PANDA II, a multicenter randomized controlled trial investigating whether thymosin alpha 1 (Tα1) supplementation can prevent organ dysfunction following acute type A aortic dissection (ATAAD) surgical repair. A total of 330 patients will be equally randomized to receive either Tα1 plus standard care or placebo plus standard care. The primary endpoint is the difference in mean postoperative Sequential Organ Failure Assessment (SOFA) scores measured daily through postoperative day 7. The scientific rationale centers on Tα1's proposed ability to rebalance post-operative immune dysregulation, thereby reducing systemic inflammatory response syndrome (SIRS)-mediated organ injury. As a protocol paper, no efficacy or outcome data are yet available. Limitations inherent to this stage include the absence of results, potential challenges in blinding given Tα1's immunological activity, and the complexity of standardizing post-surgical care across multiple centers. The trial is registered on ClinicalTrials.gov (NCT05339529). Findings will be published once the trial is completed, and this protocol represents a foundational step toward establishing evidence for Tα1 as a novel therapeutic strategy in this high-risk surgical population.
Future cardiology · May 2025DOI ↗ Insufficient
This entry reviews the available information on bremelanotide, a cyclic peptide (molecular weight ~1025 Da), specifically in the context of breastfeeding safety. The review notes a complete absence of published clinical data on bremelanotide use during lactation. The authors reason that, based on its physicochemical properties as a large cyclic peptide, transfer into breast milk is theoretically expected to be minimal. Furthermore, even if trace amounts were present in milk, oral absorption by a nursing infant would likely be negligible, as the peptide would probably be degraded by proteolytic enzymes in the infant's gastrointestinal tract. Despite this theoretical reassurance, the review concludes that caution is warranted during breastfeeding due to the lack of empirical data, with particular emphasis on vulnerability in newborn and preterm infants, whose gastrointestinal and hepatic systems are less mature. The primary limitation of this entry is that it is entirely inference-based, drawing on pharmacokinetic principles rather than any direct human or animal lactation studies. No measured milk concentration data, infant outcome data, or controlled observations are cited.
Unknown journal · Feb 2025Source ↗ Insufficient
This entry corresponds to a withdrawn article originally submitted to the journal Current Neuropharmacology, investigating the use of the stable gastric pentadecapeptide BPC 157 as a potential therapy for severe electrolyte disturbances in rats. The article was retracted at the authors' own request, and the publisher (Bentham Science) provided no details regarding the specific findings, data, or conclusions of the original study. Because the full content of the paper is unavailable — replaced entirely by a withdrawal notice — no experimental methods, results, or conclusions can be evaluated or attributed to the study. The withdrawal notice also includes standard publisher boilerplate regarding submission conditions and plagiarism policy, but does not disclose the reason for withdrawal. As a result, this record cannot be used to draw any conclusions about BPC 157's effects on electrolyte disturbances. Researchers and educators should treat this citation as non-existent in the evidence base, as the underlying data and claims are no longer accessible or endorsed by the authors or publisher.
Current neuropharmacology · Jan 2025DOI ↗ Insufficient
This cross-sectional pilot study examined the direct-to-consumer market for compounded glucagon-like peptide-1 (GLP-1) receptor agonists in Colorado. Researchers conducted Google searches of business websites advertising compounded GLP-1 products for weight loss across census-defined statistical areas between March and April 2024. They identified 93 websites corresponding to 188 physical locations. Most businesses were categorized as medical/health spas or weight loss services. Semaglutide was the most commonly advertised product (92/93 sites), followed by tirzepatide (40/93). Some sites advertised combination formulations including B vitamins, BPC-157 (flagged by the FDA as unsafe for compounding), and other additives. Seven sites advertised oral formulations. Notably, 41 of 93 websites referenced FDA approval in their product descriptions—a potentially misleading claim, as compounded products are not FDA-approved—and 5 sites incorrectly referred to products as "generic." The study's limitations include its focus on a single state, reliance on publicly available website data, and its pilot/cross-sectional design, which limits generalizability. The authors conclude that regulatory action is needed to address misleading advertising and safety concerns in this market.
Journal of pharmaceutical policy and practice · Dec 2024DOI ↗ Insufficient
SYNCHRONIZE-CVOT is a phase 3, randomized, double-blind, placebo-controlled, event-driven cardiovascular (CV) outcomes trial evaluating survodutide — a dual glucagon and GLP-1 receptor agonist administered subcutaneously once weekly — in adults with obesity or overweight (BMI ≥27 kg/m²) who also have established CV disease, chronic kidney disease, and/or at least two weight-related complications or CV risk factors. The primary endpoint is time to first occurrence of a 5-point major adverse cardiovascular event (MACE) composite. The trial targets enrollment of 4,935 participants globally and is currently in the recruitment phase (NCT06077864). The paper describes the scientific rationale — that dual glucagon/GLP-1 receptor agonism may produce greater weight reduction than GLP-1 agonism alone — and outlines the trial design in detail. As a design/rationale publication, no efficacy or safety outcomes are yet available. Key limitations at this stage include the absence of results and the event-driven nature meaning the timeline is uncertain. This trial will be the first to formally assess CV safety and potential efficacy of survodutide in a high-risk obesity population.
JACC. Heart failure · Oct 2024DOI ↗ Insufficient
This forensic laboratory study describes the analytical challenges encountered when identifying Melanotan II — a synthetic peptide informally nicknamed the "Barbie drug" — in suspected illicit drug samples submitted for analysis. Researchers used HPLC-DAD, UHPLC-TOF-MS, and UPLC-MS/MS to characterize a powder found in pharmaceutical-appearing vials labeled "Melanotan II." Standard library searches via HPLC-DAD yielded no match, partly because the UV spectrum for Melanotan II was not available in the reference library at the time. Mass spectrometric identification was further complicated by the peptide's relatively high molecular weight (~1024 Da), which exceeded the typical detection ceiling of instruments configured for classical small-molecule drugs of abuse, and by the compound's multi-charged ionization behavior. Using a reference standard, the team ultimately confirmed the identity of Melanotan II and estimated a purity of approximately 30%. The study highlights that Melanotan II is not approved for market use due to safety concerns and is sold illicitly primarily for skin tanning. The authors suggest that the significant analytical hurdles involved in detecting this peptide may partly explain its growing presence on the illicit market. This study is a descriptive forensic case report with no clinical outcome data or human subject testing.
Journal of forensic sciences · Sep 2024DOI ↗ Insufficient
This study, conducted by a doping control laboratory, describes the development and analytical validation of a method for detecting growth hormone-releasing hormones (GHRHs) — specifically tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, and somatorelin — in human urine samples. GHRHs are prohibited in sport under World Anti-Doping Agency (WADA) regulations. The method combines weak cation exchange solid-phase extraction (SPE) with ultra-high-performance liquid chromatography coupled to triple quadrupole tandem mass spectrometry (UHPLC-MS/MS). The researchers validated the method according to WADA technical documents, evaluating selectivity, limit of detection (LOD), carryover, reliability, stability, and recovery. The method achieved an LOD of 0.2 ng/mL, a limit of quantification (LOQ) of 0.6 ng/mL, and linearity from 0.1 to 1.2 ng/mL. The study reports adequate recovery and sensitivity for routine anti-doping screening. A key limitation is that this is purely an analytical/method-development study; it does not investigate pharmacological effects, clinical outcomes, or administer any compound to human or animal subjects.
Analytical biochemistry · Oct 2023DOI ↗ Insufficient
This study developed and validated an antibody-free analytical method for detecting prohibited growth hormone-releasing hormone (GHRH) analogues — specifically sermorelin, CJC-1293, a sermorelin metabolite, CJC-1295, and tesamorelin — in human urine samples. Instead of the conventional, labor-intensive immunoaffinity purification approach, the researchers used ultrafiltration alone to preconcentrate urine samples before analysis by nano liquid chromatography coupled with high-resolution tandem mass spectrometry (nanoLC-HRMS/MS). The method achieved limits of detection between 5 and 25 pg/mL and limits of identification between 25 and 50 pg/mL, with analyte recoveries of 59–115%. Robustness was demonstrated across over 200 injections. When compared directly to immunoaffinity purification, the ultrafiltration approach yielded similar sensitivity at lower cost and without requiring specialized antibodies. Stability experiments revealed that sermorelin and its metabolite degrade rapidly at temperatures above 4°C and at pH below 7, highlighting the critical importance of proper sample handling. The authors note the method could be extended to other emerging peptide drugs (≥ ~3 kDa) and their metabolites. A key limitation is that the study is an analytical methods validation paper rather than a clinical or pharmacological study; it does not assess biological effects or pharmacokinetics in human subjects.
Journal of pharmaceutical and biomedical analysis · Mar 2022DOI ↗